Literature DB >> 9066996

Cigarette smoking is associated with abnormal involuntary movements in the general male population--a study of men born in 1933.

A Nilsson1, L Waller, A Rosengren, A Adlerberth, L Wilhelmsen.   

Abstract

Abnormal involuntary movements, i.e., spontaneous and tardive dyskinesias, were studied in a random population sample of 559 men, aged 59 years, who were participating in an epidemiological study focused on cardiovascular health. The research diagnostic criteria for tardive dyskinesia were fulfilled by 8.2% (n = 46), discounting the fact that all had not been exposed to neuroleptics. The mean Abnormal Involuntary Movements Scale score in the dyskinetic group was 5.0 (SD = 1.8), indicating mild to moderate symptoms. Dyskinetic men had higher daily cigarette consumption and higher scores for parkinsonian symptoms. They also had higher frequencies of psychiatric morbidity, exposure to neuroleptics, and alcohol dependence than the men without dyskinesia. In a logistic regression model, exposure to neuroleptics (p < .05) and daily cigarette consumption (p < .0005) were independently associated with dyskinesia. The probability of dyskinesia in a person smoking 20 or more cigarettes per day was 19%, whereas the probability associated with exposure to neuroleptics was 30%.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066996     DOI: 10.1016/S0006-3223(96)00289-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  9 in total

1.  Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2011-12-05       Impact factor: 4.030

Review 2.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 3.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene.

Authors:  Siow-Ann Chong; Ene-Choo Tan; Chay Hoon Tan
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

Review 5.  Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

Authors:  Maryka Quik; Danhui Zhang; Xiomara A Perez; Tanuja Bordia
Journal:  Pharmacol Ther       Date:  2014-05-14       Impact factor: 12.310

6.  Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia.

Authors:  Xiang Yang Zhang; Da Chun Chen; Ling Yan Qi; Fang Wang; Mei Hong Xiu; Song Chen; Gui Ying Wu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

Review 7.  Necessity of oral health intervention in schizophrenic patients - A review.

Authors:  Swati Gupta; Pratibha Pk; Richa Gupta
Journal:  Nepal J Epidemiol       Date:  2016-12-31

8.  Tardive and spontaneous dyskinesia incidence in the general population.

Authors:  Ray M Merrill; Joseph L Lyon; Paul M Matiaco
Journal:  BMC Psychiatry       Date:  2013-05-28       Impact factor: 3.630

9.  Assesment of Risk Factors for Tardive Dyskinesia.

Authors:  Melek Kanarya Vardar; Mehmet Emin Ceylan; Bariş Önen Ünsalver
Journal:  Psychopharmacol Bull       Date:  2020-07-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.